Talk:Adderall

Deviant personality characteristics

Among these students, some of the risk factors for misusing ADHD stimulants recreationally include: possessing deviant personality characteristics (i.e., exhibiting delinquent or deviant behavior), inadequate accommodation of special needs, basing one's self-worth on external validation, low self-efficacy, earning poor grades, and suffering from an untreated mental health disorder.[70]

Examples of deviant personality characteristics include: deviant behavior - Seems quite open to interpretation, and I'm not sure "deviant" is the proper term to use when classifying these individuals.

Transclusion and fragility ==

This article is built by transcluding many things -- article sections, templates, and so on. That makes it quite fragile. I raised the issue over at Talk:Amphetamine/Archive 9#Transclusion, and maybe you'd like to participate there if you have ideas about how it might be improved. -- Mikeblas (talk) 15:18, 1 June 2020 (UTC)

Treatment for long-term Covid

This drug is getting prescribed to treat long-term Covid brain fog. Have read that this large new group of people who use it are putting pressure on supply in US. Also wondering about if LTC folks have good outcomes with the drug. Maybe too early to say for a W article? OrangeCounty (talk) 12:02, 31 January 2023 (UTC)

Shortages

Shortages section needs a lot of work. FDA actually first reported the shortage in I think may or june, then declared it to be over in I believe September. The actual shortage started back in 2021. There are references that mention that if people look hard enough.

It needs to be noted that shortages as reported by the FDA are based on voluntary reporting by manufacturers and is not required. And therefore do not accurately represent shortages as seen by consumers. If they choose not to report then it goes without being recognized by the FDA. So, when Teva waited till late spring I think of 2022 to bother to report their shortage, there was already a profound effect on users having issues getting their script filled and they got back lash for waiting too long. Also, manufactures tend to downplay the extent of the issue and underestimate the time to the shortage being over. All this is documented in articles if people look. I don't have the time to go back and dig every thing up again.

And if putting a shortages section. If people don't know when the other shortages were over the years, should at least mention that the most recent one is not the only one. I know there was one I believe in 2012 when I think Shire redirected the API to their Vyvanse instead of distributing it to the generic companies as they were contracted to. Causing the shortage.

There is a document in 2015 to congress from an investigation into the DEA noting all their shortcomings and failures in regards to their control of the amphetamine API and quota system from the 2012 shortage. Which can also show how they impacted and again exacerbated the current shortage.

There was at least 1 other shortage but not as bad between the 2012 and current one. Forget when it was exactly. So, I think the shortages section should be renamed to "Shortage 2021 to 2023" because "Shortages" implies more than one, and only 1 is listed skipping all the others, and the info is incorrect at that to begin with. Until someone feels like putting in effort for either title, it should be removed. 2601:86:600:A85:14B1:C34D:88DA:1EF1 (talk) 05:26, 16 May 2023 (UTC)

Please correct...

(1) Please correct the following appearing content to a scholarly understanding of molecular microbiology:

"Since the total number of microbial and viral cells..."

(2) Please do the same to the source of the content, in the referenced section of the Amphetamines article.

(3) More broadly, please consider whether this article needs such a long introductory paragraph as the one containing this sentence. The shorter following paragraph is indeed relevant to the article. In this editor's opinion, there is no need to spend as much time defining a field as presenting a specific result from it; the content giving explanatory and defining information (e.g., indicating numbers of microbial cells in the microbiome, etc.) is superfluous.

The entire first paragraph here could be replaced by one sentence with a wikilink and a citation or two (serving as an introductory sentence to the content of the current second paragraph). 73.8.193.28 (talk) 00:22, 3 December 2023 (UTC)

Insufflation

Why is insufflation listen as a method of administration of adderall in the sidebar? Themckinlay (talk) 13:52, 2 August 2024 (UTC)

Article is biased.

Article is very biased. Same rhetoric propagated all too often. Negative effects are in context of abuse. Adderall can cause the same issues at prescribed levels as at the abused levels, only slower. Always stating the negative in terms of abuse is a "blame the victim" narrative for anyone with issues at therapeutic doses. Even ICD10 and ICD11 codes for side effects from amphetamine states it can occur at therapeutic prescribed doses. Although the listed number of possible side effects is quite limiting. Research, especially in adults has shown this too.

I apologize for not having all the links for all these things as this is not being written on my computer.

Article mentions young children who start on Adderall are less likely to become addicts when they get older. What they fail to mention is that starting in adolescents or adulthood, people are more likely to become addicts as they are more willing to self medicate or seek a euphoric dose.

Missing is one of the primary effects of amphetamine is the AMPA/NMDA antagonism causing glutamate release. And believed by many researchers to be the primary way amphetamine builds tolerance.

Also lacking is many of the ways amphetamine causes downregulation and damage. --adderall can be exciteotoxic to the NMDA/glutamatergic pathways. Over excitement causes downregulation of receptors and excess ion flux causes oxidative stress in the cell that can lead to disregulation or even apoptosis. Excess glutamate triggers extrasynaptic NMDA receptors which is the trigger for the apoptosis cascade. Many researchers believe this to be the primary way amphetamine builds tolerance. And why some therapist prescribe the NMDA uncompetitive antagonist memantine to prevent or reduce tolerance. --Does mention the phosphorilization of DAT and NAT. But does not mention that this is acute tolerance and causes a need for a higher blood API concentration in the afternoon just to maintain the same therapeutic efficiency as the morning. And why the standard recommended dosage is the same dose separated by about 4 hours, which nearly doubles the BAC to maintain steady therapeutic effect and how Adderall XR was designed. I do have an article for the readily available. Shows acute tolerance, therapeutic dose curve during the day. But before they understood acute tolerance is from phosphorilization of DAT and NAT and likely other pathways like NMDA. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547091/ --VMAT2 can get downregulated or cause dysfunction. --Amphetamine can diffuse through the cell wall, doesn't just use DAT or NAT transports. And can diffuse through mitochondria wall which it can cause oxidative stress in mitochondria. --Can't recall if MOA antagonism was mentioned, but it can cause damage or downregulation too. --A lot of the catecholamines get stuck in the cytosol which auto-oxidizes leading to oxidative stress. As does excess in the synapse and extra-synaptic space. --Does regulation of tyrosine hydroxylase has been shown can happen with long term use. --A know there are other neurological factors I don't recall.

Endocrine side effects was not even mentioned. Less research but it does exist. Even the FDA approved accompanying literature mentions endocrine effects but very lacking in longer term effects. --A THE and cortisol decrease during the day. amphetamine has the opposite effect on it. --Can cause testosterone/estrogen imbalance in part due to weak estrogenic property of amphetamine. But likely due to other reasons too. Which in men has low T symptoms. --Can decrease LH and FSH which can effect fertility. --Can cause stimulant induced secondary gynecomastia. Which can be distinguished from other forms of gynecomastia by stimulant use, estrogen dominance, normal or low levels of LH and FSH. --Can increase cAMP, which I don't recall for sure but may have been a side effect of high ACTH. --There are some others I forget off the top of my head.

Only references an article in which it states higher dose users can take up to 4 weeks to recover from stopping medication. Doesn't mention that is not true for everyone and although not frequent, some people can take 6 months to a year, even from prescribed high doses. Has been shown in other studies that even at low doses there is a significant number of patients who show accumulated tolerance and stopping medication worsens ADHD symptoms for a while. Amphetamine can also cause irreversible damage for some people while addicts can also often make a full recovery.

There is some study on how adults respond differently to the medication, especially in the long run. But also acknowledge adult research is still lacking in many ways.

Many studies on CNS stimulants stunting growth say on stopping medication, growth resumes and is unaffected. While other studies show a decrease final height even after stopping medication that is statistically significant compared to placebo group. Think on average it may have been a 1/2 inch shorter but not sure. Don't recall reading studies on children who stayed on longer after stunted growth was recognized. Which doesn't mention the underlying cause but likely something in the endocrine system.

My opinion, but shared by many researchers. Pharmacology for ADHD drugs are based on short term studies in young and adolescent children to establish therapeutic efficiency, short term side effects profile, and therapeutic dosage range. Performed and paid for by drug companies to pass FDA approval to make money selling their product. These are reflected as the guidelines in the DSM-V as well as psychiatrist and neurologist curriculum. Which includes the drug companies taking points framing the narrative to their benefit. Adult dosage range was assumed from child studies. Research in adults just showed effect for the existing adolescents dosage range. None of these account for the dynamic therapeutic dosage range caused by tolerance. There is plenty of funding from big pharma for things in their interest. But a lack of funding for things that go against their narratives. If someone gets bored, they can compare the approved accompanying literature changes between releases and see how lacking info was till more recently. Which is still very lacking. Even some contradictions between Adderall and Adderall XR if you've read the XR design article

HCStymie (talk) 21:58, 5 August 2024 (UTC)

1. Can you reword your concerns as bullet point sentences instead of paragraphs? It's quite difficult to understand what content you believe violates policy a la WP:NPOV.

2. If/when rewording your concerns as bullet point sentences, can you also quote specific excerpts from the article that you believe violate policy?

Thanks. Professional Crastination (talk) 12:38, 6 August 2024 (UTC)

MAS title usage

@Gobucks821 I've reverted the changes you made Re: substituting Adderall for "MAS products" throughout the article.

Adderall is the title of this article and the usage of Adderall to refer to the specific amphetamine salt composition in both Adderall and Mydayis dosage formulations is underpinned by previous consensus on this article's talk page. Moreover, the note in the title sentence of this article clarifies the usage of Adderall throughout the article.

For those reasons, in future you need to gain consensus on this article's talk page before making a change like that. Professional Crastination (talk) 05:02, 7 August 2024 (UTC)